Camrelizumab Combined With Radiotherapy for Adjuvant Treatment of Esophageal Squamous Cell Carcinoma After Surgery
Status:
Recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
This is an investigator-initiated, single-arm, single-center, exploratory clinical study.The
study population consisted of patients with R0 resection of esophageal squamous cell
carcinoma who had not received radiation therapy.The purpose of this study was to evaluate
the efficacy and safety of carrelizumab combined with radiotherapy in the adjuvant treatment
of esophageal squamous cell carcinoma after surgery.About 20 subjects are planned to be
enrolled in this study.Drug regimen: Patients with esophageal squamous cell carcinoma
received radiotherapy combined with carrilizumab adjuvant therapy for 6 cycles 1-3 months
after R0 resection.